Breast Cancer

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

The use of chemotherapy trended toward improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

In the phase 3 DESTINY-Breast06 trial, the overall biomarker-evaluable population’s confirmed ORR was 59.4% with T-DXd vs 33.9% with chemotherapy.

Across all 3 treatment arms, global health status/quality of life and functional domains were maintained in the phase 3 EMBER-3 trial.

Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.

T-DXd rechallenge occurred after grade 1 ILD, and was proven safe for patients with breast cancer/solid tumors.

PFS was improved with first-line sacituzumab govitecan plus pembrolizumab for patients with PD-L1–positive metastatic TNBC.

Vepdegestrant shows significant clinical activity and a favorable safety profile in ESR1-mutant HER2-negative, ER-positive metastatic breast cancer vs fulvestrant.

Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.

In the phase 3 ASCENT-03 trial, sacituzumab govitecan did not show an OS detriment vs chemotherapy in previously untreated metastatic triple-negative breast cancer.

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.